Leadership

Trey Ideker

Scientific Co-Founder

Trey Ideker is a Professor of Medicine, Bioengineering and Computer Science at the University of California, San Diego. A world leader in systems and network biology, Trey has pioneered the use of machine learning to build mechanistic models of cancer and other human diseases. He directs or co-directs the National Resource for Network Biology, and the Cancer Cell Map and Psychiatric Cell Map Initiatives. His work has appeared in publications such as Nature, Science, and Cell and has been cited >92K times.

Maxwell Sherman

Co-Founder & CTO

Adam Yaari

Co-Founder & CEO

Prior to founding Serinus, Max spent 15+ years at the intersection of medicine, biology, and mathematics at MIT, Harvard Medical School, University of Cambridge, and Brown University. He has devoted his career to developing novel tools and treatments for underserved patient populations.
Max is the recipient of multiple national and international research awards, and his work has been published in top journals, including Science, Nature Biotechnology, and Nature Neuroscience.
Max received his PhD in computational biology from MIT, masters in mathematics from the University of Cambridge, and BS in applied mathematics & biology from Brown University.
Fun fact: Max began his medical journey by spending 5 years working in the back of an ambulance.
Twitter — Linkedin

Prior to founding Serinus, Adam spearheaded AI research for biomedical applications, including at Microsoft and Flagship Pioneering. With 15+ years of leadership and entrepreneurship experience, Adam is passionate about building computation-first therapeutic platforms to expand precision medicine to more patients.
Adam has co-authored multiple peer-reviewed papers with Max and his work has been published in top journals and conferences, including Nature Biotechnology, PNAS, and ICLR.
Adam received his PhD and MS in computer science from MIT, MSc in computer science and mathematics from the Weizmann Institute of Science, and graduated Summa Cuma Laude with dual majors in computer science and neuroscience from the Bar-Ilan University.
Fun fact: before his academic trajectory Adam served as a Navy elite unit team commander.
Twitter — Linkedin

Sabine Ruppel

SVP of Drug Discovery

Prior to Serinus, Sabine served as the VP of Drug Discovery at Ikena Oncology, managing a cross-functional team of medicinal chemistry, DMPK, biochemistry/biophysics, structural research, and computational chemistry. Prior to Ikena Oncology, Sabine held roles of increasing responsibility in computational and medicinal chemistry across Berlex Biosciences, Boehringer Ingelheim, Forma Therapeutics, H3 Biomedicine, and Foghorn Therapeutics.
With 25+ years of experience, Sabine has contributed to the discovery and early development of multiple clinical candidates, most recently she led a MEK-RAF molecular glue program from discovery to the clinic. She is a co-inventor of over 50 patent filings.
Sabine earned her BA and PhD in Chemistry from the University of California, Davis.
Fun fact: Sabine traveled all the way to Hudson Bay, Canada, just to see polar bears in their natural habitat.
Linkedin

Bonnie Berger

Technical Co-Founder

Bonnie Berger is the Simons Professor of Mathematics at MIT. She is a foundational pioneer of computational molecular biology, having contributed widely to nearly every domain of genomics. She and her students have fundamentally advanced structure-based protein determination, drug-target and target-target interaction prediction, and genome sequence analysis. She is the recipient of the distinguished ISCB Senior Scientist Award and an elected member of the American Academy of Arts and Sciences.

Eliezer Van Allen

Scientific Advisor

William Hahn

Scientific Advisor

Peter Hammerman

Scientific Advisor

Peter is the Chief Scientific Officer of MOMA Therapeutics, where he is responsible for overseeing a pipeline of oncology therapeutics from target identification through early clinical development. Peter is a widely recognized leader in oncology therapeutic development, having spent nearly five years as global head of translational research at the Novartis Institutes of Biomedical Research and eight years as a physician-scientist at the Dana Farber Cancer Institute. Peter has published more than 100 peer-reviewed papers on topics such as experimental therapeutics, genomics, and biomarker development.

William Hahn is the William Rosenberg Professor of Medicine in the Department of Medical Oncology at Dana-Farber Cancer Institute and Harvard Medical School, an Institute Member of the Broad Institute, and Executive Vice President and the Chief Operating Officer at the Dana-Farber Cancer Institute. Dr. Hahn and his lab have pioneered functional genomic approaches to identify and validate cancer targets. These tools are now used worldwide to discover and validate molecularly targeted cancer therapies.

Eliezer Van Allen is the Chief of the Division of Population Sciences at the Dana-Farber Cancer Institute and Associate Professor of Medicine at Harvard Medical School. His lab advances precision oncology using new techniques in molecular biology and machine learning to study resistance and metastasis mechanisms. His research fundamentally shaped understanding of resistance to Raf inhibitors and immunotherapy, leading to improved treatment responses in otherwise refractory patients.